Evidence map›Paper›PMID 41115170›Full record

ReviewAnnual review of medicine2026

Contemporary Treatment Strategies in Pulmonary Hypertension: A Clinician's Guide.

Brandon Budhram, Samuel Chung, Marc Humbert, Evelyn Horn

Abstract readReview
In one paragraph

Review in Annual review of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brandon BudhramDivision of Respirology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Samuel ChungDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Marc HumbertUniversité Paris-Saclay, INSERM Unité Mixte de Recherche en Santé 999, Hypertension Pulmonaire, Physiopathologie et Innovation Thérapeutique (HPPIT), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre (Assistance Publique-Hôpitaux de Paris), European Reference Network for Rare Respiratory Diseases, Le Kremlin-Bicêtre, France.
Evelyn HornDivision of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA; email: horneve@med.cornell.edu.

Funding

Purposeful Outreach for Diversity and Inclusion of Underrepresented in Medicine (PODIUM) Physician-ScientistsT32HL172255 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Carmen R. Isasi, Marina Reznik · 2024 to 2026
$936k
NHLBI NIH HHS T32 HL172255
6 · The paper itself

Abstract

Pulmonary hypertension (PH) is a complex condition characterized by pulmonary vasculopathy and progressive right ventricular dysfunction. Recent advances have reshaped PH management, including refined risk stratification, improved patient phenotyping, and the discovery of novel therapeutics. In alignment with the recommendations of the Seventh World Symposium on Pulmonary Hypertension, we summarize updated treatment strategies and emerging therapies, such as sotatercept, while acknowledging research gaps and areas of clinical equipoise. This practical, evidence-based review explores treatment across all groups of PH to inform clinical decision-making, improve long-term patient outcomes, and address both current and future challenges in PH management.

Indexed as

Hypertension, PulmonaryAntihypertensive AgentsHumansPractice Guidelines as TopicAntihypertensive Agentsphenotypingpulmonary hypertensionrisk stratificationsotatercepttherapeutic strategiestreatment algorithm

Identifiers

PMID41115170
PMCPMC12614744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.